31 May 2016

Flintstone confirms Biocote float

As foreshadowed here in early November, investment company Flinstone Technologies, which today released interim figures, has revealed plans to float one of its investments, powder coatings outfit Biocote, on Aim next year.

Flintstone, which joined Aim in June raising £4.5 million net at 33p per share, has stakes in five different early-stage ventures, many originally developed by Russian scientists. In the six months to the end of September the group made a £669,000 operating loss, 17 per cent more than in the corresponding period in 2001.

The powdering process behind Biocote, which was created in Wolverhampton, creates hygienic surfaces for use in healthcare, food processing, white goods, such as fridges, and other appliances. An early stage investor was the first Oxford Technology Venture Capital Trust.

Flintstone picked up a 25 per cent stake in the group two years ago, subsequently increased to 40 per cent, and now wants to realise an exit by floating the company on Aim. At the end of last year Oxford Technology, which retains a 10 per cent stake in the group, valued Biocote at just £555,000.

Flintstone chairman Glyn Hirsch claims the company is 'nearing profitability' and now wants to raise more money in a placing to 'expand the business' and so is preparing the company for admission to Aim 'during the first half of 2003'.

Oxford Technology's second VCT has invested in another of Flintstone's companies, Hardide. This developer of super-resistant coating for metal machinery, which enhances their performance, is completing a £2 million fundraising, which will reduce Flinstone's stake from 55 per cent to 45 per cent.

Hardide, which is a Russian idea, is valued at £2 million. The fresh funds will enable it to buy manufacturing plant and move to fresh premises.

Another Russian enterprise, rechargeable battery developer Intellikraft, is struggling following the departure of Yuri Spirin as chief executive, who founded the company from scratch.

Flintstone's shares have fallen 13.5p, or over a third, to 19.5p since flotation. The company is currently worth £9.27 million, nearly twice its net asset value at these results of £4.98 million.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

A new Angle on cancer diagnostics

Medical device manufacturer Angle (AIM: AGL) has raised a further £10 million through a placing at 64.5p. Angle has an exciting technology which has recently registered its first commercial sales. This extra cash will help to accelerate its marketing efforts and advance the research projects being carried out in major cancer centres.

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

More News